Skip to main content
. 2023 Oct 9;15(11):e17810. doi: 10.15252/emmm.202317810

Figure EV5. Combination of HIF2α inhibition and ATRA increases AML differentiation in NB4, Molm13, and THP1 cells.

Figure EV5

  1. Percentages of CD11b+ NB4 (left graph), Molm13 (middle graph) and THP1 (right graph) cells with shRNAs against HIF1α, HIF2α, or a scrambled shRNA as control (shCTRL) treated with 1 μM ATRA for 2 days. Data represent mean ± SD of three biological replicates (one‐way ANOVA followed by Tukey's multiple comparison test).
  2. Percentages of CD11b+ NB4 (left graph), Molm13 (middle graph) and THP1 (right graph) cells following treatment with 50 μM PT2385, 1 μM ATRA, or combination for 4 days. Data represent mean ± SD of three biological replicates (one‐way ANOVA followed by Tukey's multiple comparison test).
  3. Percentages of NB4 (left graph), Molm13 (right graph) and THP1 (lower graph) cells in the indicated phases of the cell cycle following treatment with 50 μM PT2385, 1 μM ATRA, or combination for 4 days. Data represent mean ± SD of three biological replicates (Student's t‐test).